EUVIMEDEUVIMED entdecken
Crossref

Toxicologic Neuropathology of Novel Biotherapeutics

Dinesh S Bangari iD, Lisa G Lanigan iD, Sarah D Cramer, Jessica L Grieves iD, René Meisner, Arlin B Rogers, Elizabeth J Galbreath, Brad Bolon iD

Toxicologic Pathology · 2023

DOI: 10.1177/01926233241230542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicologic Pathology, 2023. Verfasst von Dinesh S Bangari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Neuropathology, Nucleic Acids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 168 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biotherapeutic modalities such as cell therapies, gene therapies, nucleic acids, and proteins are increasingly investigated as disease-modifying treatments for severe and life-threatening neurodegenerative disorders. Such diverse bio-derived test articles are fraught with unique and often unpredictable biological consequences, while guidance regarding nonclinical experimental design, neuropathology evaluation, and interpretation is often limited. This paper summarizes key messages offered during a half-day continuing education course on toxicologic neuropathology of neuro-targeted biotherapeutics. Topics included fundamental neurobiology concepts, pharmacology, frequent toxicological findings, and their interpretation including adversity decisions. Covered biotherapeutic classes included cell therapies, gene editing and gene therapy vectors, nucleic acids, and proteins. If agents are administered directly into the central nervous system, initial screening using hematoxylin and eosin (H&E)-stained sections of currently recommended neural organs (brain [7 levels], spinal cord [3 levels], and sciatic nerve) may need to expand to include other components (e.g., more brain levels, ganglia, and/or additional nerves) and/or special neurohistological procedures to characterize possible neural effects (e.g., cell type-specific markers for reactive glial cells). Scientists who evaluate the safety of novel biologics will find this paper to be a practical reference for preclinical safety testing and risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuropathologyNucleic AcidsBrainSpinal CordSciatic Nerve

Stichwörter der Autor:innen

antisense oligonucleotidescell therapygene therapyneuropathologypreclinical safety testingshort interfering ribonucleic acidstherapeutic antibodies

Substanzen

Nucleic Acids

Autor:innen und Institutionen

  • Sanofi, Cambridge, Massachusetts, USA.
  • Charles River Laboratories, Ashland, Ohio, USA.
  • StageBio, Frederick, Maryland, USA.
  • Ionis Pharmaceuticals, Carlsbad, California, USA.
  • Denali Therapeutics, South San Francisco, California, USA.
  • Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

ORCID-Profile: Dinesh S Bangari, Lisa G Lanigan, Jessica L Grieves, Brad Bolon

Zitieren

APA

Bangari, D. S., Lanigan, L. G., Cramer, S. D., Grieves, J. L., Meisner, R., Rogers, A. B., Galbreath, E. J., & Bolon, B. (2023). Toxicologic Neuropathology of Novel Biotherapeutics. Toxicologic Pathology. https://doi.org/10.1177/01926233241230542

Vancouver

Bangari DS, Lanigan LG, Cramer SD, Grieves JL, Meisner R, Rogers AB, et al. Toxicologic Neuropathology of Novel Biotherapeutics. Toxicologic Pathology. 2023. doi:10.1177/01926233241230542

BibTeX
@article{Bangari2023,
  author = {Bangari, Dinesh S and Lanigan, Lisa G and Cramer, Sarah D and Grieves, Jessica L and Meisner, René and Rogers, Arlin B and Galbreath, Elizabeth J and Bolon, Brad},
  title = {Toxicologic Neuropathology of Novel Biotherapeutics},
  journal = {Toxicologic Pathology},
  year = {2023},
  doi = {10.1177/01926233241230542}
}
Kostenlos starten →